LOX and osteosarcoma: (1) In osteosarcoma, LOX-high stromal programs track with a stiffened ECM, M2-like macrophage polarization, and pro-invasive niches; pharmacologic LOX inhibition reverses invasive phenotypes and increases tumor cell death in preclinical models.